Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor

BACKGROUND AND OBJECTIVE: Roxadustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor in phase III development for the treatment of anaemia associated with chronic kidney disease. This study evaluated the effects of moderate hepatic impairment on roxadustat pharmacokinetics, pharmacodynami...

Descripción completa

Detalles Bibliográficos
Autores principales: Groenendaal-van de Meent, Dorien, Adel, Martin den, Noukens, Jan, Rijnders, Sanne, Krebs-Brown, Axel, Mateva, Lyudmila, Alexiev, Assen, Schaddelee, Marloes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2016
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4987405/
https://www.ncbi.nlm.nih.gov/pubmed/27352308
http://dx.doi.org/10.1007/s40261-016-0422-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4987405/
https://www.ncbi.nlm.nih.gov/pubmed/27352308
http://dx.doi.org/10.1007/s40261-016-0422-y

Ejemplares similares